Literature DB >> 28165337

A mouse model of MYCN-driven retinoblastoma reveals MYCN-independent tumor reemergence.

Nan Wu, Deshui Jia, Breanna Bates, Ryan Basom, Charles G Eberhart, David MacPherson.   

Abstract

The most frequent focal alterations in human retinoblastoma are mutations in the tumor-suppressor gene retinoblastoma (RB) and amplification of the oncogene MYCN. Whether MYCN overexpression drives retinoblastoma has not been assessed in model systems. Here, we have shown that Rb inactivation collaborates strongly with MYCN overexpression and leads to retinoblastoma in mice. Overexpression of human MYCN in the context of Rb inactivation increased the expression of MYC-, E2F-, and ribosome-related gene sets, promoted excessive proliferation, and led to retinoblastoma with anaplastic changes. We then modeled responses to MYCN-directed therapy by suppressing MYCN expression in MYCN-driven retinoblastomas. Initially, MYCN suppression led to proliferation arrest and partial tumor regression with loss of anaplasia. However, over time, retinoblastomas reemerged, typically without reactivation of human MYCN or amplification of murine Mycn. A subset of returning retinoblastomas showed genomic amplification of a Mycn target gene encoding the miR cluster miR-17~92, while most retinoblastomas reemerged without clear genetic alterations in either Mycn or known Mycn targets. This Rb/MYCN model recapitulates key genetic driver alterations seen in human retinoblastoma and reveals the emergence of MYCN independence in an initially MYCN-driven tumor.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28165337      PMCID: PMC5330763          DOI: 10.1172/JCI88508

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  54 in total

1.  Extraction, purification and analysis of histones.

Authors:  David Shechter; Holger L Dormann; C David Allis; Sandra B Hake
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

2.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

3.  Cooperation between Rb and Arf in suppressing mouse retinoblastoma.

Authors:  Karina Conkrite; Maggie Sundby; David Mu; Shizuo Mukai; David MacPherson
Journal:  J Clin Invest       Date:  2012-04-09       Impact factor: 14.808

4.  c-Myc-regulated microRNAs modulate E2F1 expression.

Authors:  Kathryn A O'Donnell; Erik A Wentzel; Karen I Zeller; Chi V Dang; Joshua T Mendell
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

5.  Genetic dissection of the miR-17~92 cluster of microRNAs in Myc-induced B-cell lymphomas.

Authors:  Ping Mu; Yoon-Chi Han; Doron Betel; Evelyn Yao; Massimo Squatrito; Paul Ogrodowski; Elisa de Stanchina; Aleco D'Andrea; Chris Sander; Andrea Ventura
Journal:  Genes Dev       Date:  2009-12-15       Impact factor: 11.361

6.  MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma.

Authors:  Jakob Lovén; Nikolay Zinin; Therese Wahlström; Inga Müller; Petter Brodin; Erik Fredlund; Ulf Ribacke; Andor Pivarcsi; Sven Påhlman; Marie Henriksson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

7.  Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras.

Authors:  Katrina Podsypanina; Katerina Politi; Levi J Beverly; Harold E Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-20       Impact factor: 11.205

8.  Germline deletion of the miR-17∼92 cluster causes skeletal and growth defects in humans.

Authors:  Loïc de Pontual; Evelyn Yao; Patrick Callier; Laurence Faivre; Valérie Drouin; Sandra Cariou; Arie Van Haeringen; David Geneviève; Alice Goldenberg; Myriam Oufadem; Sylvie Manouvrier; Arnold Munnich; Joana Alves Vidigal; Michel Vekemans; Stanislas Lyonnet; Alexandra Henrion-Caude; Andrea Ventura; Jeanne Amiel
Journal:  Nat Genet       Date:  2011-09-04       Impact factor: 38.330

9.  HTSeq--a Python framework to work with high-throughput sequencing data.

Authors:  Simon Anders; Paul Theodor Pyl; Wolfgang Huber
Journal:  Bioinformatics       Date:  2014-09-25       Impact factor: 6.937

10.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data.

Authors:  Mark D Robinson; Davis J McCarthy; Gordon K Smyth
Journal:  Bioinformatics       Date:  2009-11-11       Impact factor: 6.937

View more
  20 in total

Review 1.  Retinoblastoma, the visible CNS tumor: A review.

Authors:  Helen Dimaras; Timothy W Corson
Journal:  J Neurosci Res       Date:  2018-01-03       Impact factor: 4.164

2.  Developmental stage-specific proliferation and retinoblastoma genesis in RB-deficient human but not mouse cone precursors.

Authors:  Hardeep P Singh; Sijia Wang; Kevin Stachelek; Sunhye Lee; Mark W Reid; Matthew E Thornton; Cheryl Mae Craft; Brendan H Grubbs; David Cobrinik
Journal:  Proc Natl Acad Sci U S A       Date:  2018-09-13       Impact factor: 11.205

Review 3.  Therapeutic targeting of oncogenic transcription factors by natural products in eye cancer.

Authors:  Michelle G Zhang; John Y Lee; Ryan A Gallo; Wensi Tao; David Tse; Ravi Doddapaneni; Daniel Pelaez
Journal:  Pharmacol Res       Date:  2017-12-02       Impact factor: 7.658

Review 4.  The Role of Glypicans in Cancer Progression and Therapy.

Authors:  Nan Li; Madeline R Spetz; Mitchell Ho
Journal:  J Histochem Cytochem       Date:  2020-07-06       Impact factor: 2.479

5.  MYCN induces cell-specific tumorigenic growth in RB1-proficient human retinal organoid and chicken retina models of retinoblastoma.

Authors:  Maria K E Blixt; Minas Hellsand; Dardan Konjusha; Hanzhao Zhang; Sonya Stenfelt; Mikael Åkesson; Nima Rafati; Tatsiana Tararuk; Gustav Stålhammar; Charlotta All-Eriksson; Henrik Ring; Finn Hallböök
Journal:  Oncogenesis       Date:  2022-06-21       Impact factor: 6.524

6.  CDK14 involvement in proliferation migration and invasion of esophageal cancer.

Authors:  Lingling Chen; Yayun Wang; Wenyan Jiang; Runzhou Ni; Yuchan Wang; Sujie Ni
Journal:  Ann Transl Med       Date:  2019-11

Review 7.  Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3.

Authors:  Nan Li; Madeline R Spetz; Dan Li; Mitchell Ho
Journal:  Pharmacol Ther       Date:  2021-05-14       Impact factor: 13.400

Review 8.  Heterogeneity in retinoblastoma: a tale of molecules and models.

Authors:  Sonya Stenfelt; Maria K E Blixt; Charlotta All-Ericsson; Finn Hallböök; Henrik Boije
Journal:  Clin Transl Med       Date:  2017-11-09

9.  MYCN is a novel oncogenic target in adult B-ALL that activates the Wnt/β-catenin pathway by suppressing DKK3.

Authors:  Desheng Kong; Linlin Zhao; Lili Sun; Shengjin Fan; Huibo Li; Yanqiu Zhao; Zhibo Guo; Leilei Lin; Lin Cui; Ke Wang; Wenjia Chen; Yihui Zhang; Jin Zhou; Yinghua Li
Journal:  J Cell Mol Med       Date:  2018-04-19       Impact factor: 5.310

10.  Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer.

Authors:  Nicholas J Brady; Alyssa M Bagadion; Richa Singh; Vincenza Conteduca; Lucie Van Emmenis; Elisa Arceci; Hubert Pakula; Ryan Carelli; Francesca Khani; Martin Bakht; Michael Sigouros; Rohan Bareja; Andrea Sboner; Olivier Elemento; Scott Tagawa; David M Nanus; Massimo Loda; Himisha Beltran; Brian Robinson; David S Rickman
Journal:  Nat Commun       Date:  2021-06-07       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.